Winston-Salem, North Carolina Oct 30, 2008
Targacept, Inc. (NASDAQ: TRGT), a clinical-stage biopharmaceutical company developing a new class of drugs known as NNR Therapeutics (TM), today announced that it will conduct a conference call and audio webcast at 5:00 p.m. Eastern Standard Time on Thursday, November 6, 2008 following the after-market release of its financial results for the third quarter ended September 30, 2008. J. Donald deBethizy, Ph.D., President and Chief Executive Officer, and Alan A. Musso, Vice President and Chief Financial Officer, will host the call, during which they will discuss Targacept’s financial results and provide an update on the company's product development programs and business activities.
A live webcast of the conference call will be accessible from the Investor Relations page of Targacept’s website, www.targacept.com. To ensure a timely connection to the webcast, it is recommended that users register at least 15 minutes prior to the scheduled start time. An archived version of the webcast will also be available on Targacept’s website for at least two weeks following the call.
The conference call may be accessed by dialing 866-578-5801 for domestic participants and 617-213-8058 for international callers (reference passcode 91046070). A replay of the conference call may be accessed through November 20, 2008 by dialing 888-286-8010 for domestic callers and 617-801-6888 for international callers (reference passcode 42586408).
About Targacept
Targacept is a clinical-stage biopharmaceutical company that discovers and develops NNR Therapeutics™, a new class of drugs for the treatment of central nervous system diseases and disorders. Targacept's product candidates selectively modulate neuronal nicotinic receptors that serve as key regulators of the nervous system to promote therapeutic effects and limit adverse side effects. Targacept has product candidates in development for Alzheimer's disease, cognitive dysfunction in schizophrenia, pain and depression, as well as multiple preclinical programs. Targacept also has a cognition-focused collaboration with AstraZeneca and a strategic alliance with GlaxoSmithKline. Targacept’s news releases are available on its website at www.targacept.com.
Contacts:
Alan Musso, VP and CFO
Targacept, Inc.
Telephone: 336-480-2186
Email: alan.musso@targacept.com
Michelle Linn
Linnden Communications
Telephone: 508-362-3087
Email: michelle@linndencom.com